EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation

Georg Nickenig, Philipp Lurz, Paul Sorajja, Ralph Stephan von Bardeleben, Marta Sitges, Gilbert H L Tang, Jörg Hausleiter, Jean-Noel Trochu, Michael Näbauer, Megan Heitkemper, Shih-Wa Ying, Marcel Weber und 2 weitere

JACC: Cardiovascular Interventions · 2024-09 · 17 (18) · 2113-2122

DOI: 10.1016/j.jcin.2024.05.036 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024-09. Verfasst von Georg Nickenig und 13 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center University Hospital Bonn, Bonn, Germany. Electronic address: Georg.Nickenig@ukbonn.de. Hauptthemen laut MEDLINE: Cardiac Catheterization, Quality of Life, Recovery of Function, Severity of Illness Index. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tricuspid regurgitation (TR) is a common valve disease that has a significant impact on patients' quality of life. OBJECTIVES: This study sought to report the final 3-year outcomes of tricuspid transcatheter edge-to-edge repair (T-TEER) with the TriClip (Abbott) implant from the TRILUMINATE (TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR) study for the treatment of severe symptomatic TR. METHODS: The TRILUMINATE study (N = 98 subjects) is an international, prospective, single-arm, multicenter study to investigate the safety and performance of T-TEER with the TriClip implant in patients with symptomatic moderate or greater TR. Echocardiographic assessments were performed at a core laboratory. RESULTS: At 3 years, TR was reduced to moderate or less in 79% of subjects, and a reduction of at least 1 grade was achieved in 92% of subjects. TR reduction achieved at 1 year was sustained through 3 years. Subjects also experienced an improvement in heart failure symptoms assessed by NYHA functional class and quality of life assessed by the Kansas City Cardiomyopathy Questionnaire at 3 years compared to baseline. The site-reported heart failure hospitalization rate decreased from 0.56 events/patient-year 1 year before device implantation to 0.14 events/patient-year 3 years after device implantation, representing a reduction of 75% (P < 0.0001). CONCLUSIONS: In the longest follow-up to date of any T-TEER therapy, the TRILUMINATE study demonstrated that the TriClip procedure is both safe and effective, with sustained benefits at 3 years in subjects with symptomatic moderate or greater TR. (TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR [TRILUMINATE]; NCT03227757).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiac CatheterizationQuality of LifeRecovery of FunctionSeverity of Illness IndexTricuspid ValveTricuspid Valve InsufficiencyAgedAged, 80 and overFemaleHumansMaleMiddle AgedEuropeFunctional StatusProspective StudiesProsthesis DesignTime FactorsTreatment OutcomeUnited States

Stichwörter der Autor:innen

TEERTriClipleaflet repairtricuspid regurgitationtricuspid repair

Autor:innen und Institutionen

  • Heart Center University Hospital Bonn, Bonn, Germany. Electronic address: Georg.Nickenig@ukbonn.de.
  • Heart and Vascular Center, University Medical Center Mainz, Mainz, Germany.
  • Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
  • Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Centro de Investigación Biomedica en Red Enfermedades Cardiovasculares, Barcelona, Spain.
  • Mount Sinai Heath System, New York, New York, USA.
  • Medizinische Klinik und Poliklinik I der Ludwig- Maximilians-Universität München, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.

Zitieren

APA

Nickenig, G., Lurz, P., Sorajja, P., von Bardeleben, R. S., Sitges, M., Tang, G. H. L., Hausleiter, J., Trochu, J. N., Näbauer, M., Heitkemper, M., Ying, S. W., Weber, M., Hahn, R. T., & TRILUMINATE Investigators (2024). Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 17(18), 2113-2122. https://doi.org/10.1016/j.jcin.2024.05.036

Vancouver

Nickenig G, Lurz P, Sorajja P, von Bardeleben RS, Sitges M, Tang GHL, et al. Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation. JACC: Cardiovascular Interventions. 2024;17(18):2113-2122. doi:10.1016/j.jcin.2024.05.036

BibTeX
@article{Nickenig2024,
  author = {Nickenig, Georg and Lurz, Philipp and Sorajja, Paul and von Bardeleben, Ralph Stephan and Sitges, Marta and Tang, Gilbert H L and Hausleiter, Jörg and Trochu, Jean-Noel and Näbauer, Michael and Heitkemper, Megan and Ying, Shih-Wa and Weber, Marcel and Hahn, Rebecca T and TRILUMINATE Investigators, TRILUMINATE Investigators},
  title = {Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  volume = {17},
  number = {18},
  pages = {2113--2122},
  doi = {10.1016/j.jcin.2024.05.036}
}
Kostenlos starten →